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Conclusion: Treatment intensification in NSCLC via targeted 
dose escalation with modern delivery techniques offers the 
potential for a significant increase in tumour control 
probability without a clinically significant increase in 
predicted OAR toxicity. 
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Purpose or Objective: We investigated the associations 
between acute and late genitourinary (grade ≥ 2) toxicity and 
clinical and dosimetric parameters in three-dimensional 
conformal radiotherapy for localized prostate cancer in order 
to carry out a dose-volume response evaluation. A dose-
volume parameters analysis of the bladder of patients 
subjected to prostate cancer radiotherapy was reported. 
 
Material and Methods: We considered 86 patients 
consecutively treated with high dose conformal image guided 
radiation therapy for localized prostate cancer. For the 
purpose of our analysis, we defined two bladder volumes: 
“whole bladder”, i.e. the bladder in its entirely as a solid 
organ, and “inferior bladder”, corresponding to the only 
distal part of the bladder. We carried out an univariate 
analysis between acute and late genitourinary toxicity and 
clinical parameters (age, “whole bladder” and “inferior 
bladder” volumes, smoking status, pre-radiotherapy urinary 
symptoms, hormonal therapy). We used the point biserial 
correlation coefficient to correlate dose-volume parameters 
(Vx) and genitourinary (grade ≥ 2) toxicity. Finally, a fitting 
of the normal tissue complication probability (NTCP) cut-off 
volume model with toxicity data was performed. 
 
Results: Mean follow-up was 51.9 months (range: 41.9–75.4 
months). In 60 patients we observed an acute genitourinary 
toxicity (grade ≥2), while a late genitourinary toxicity (grade 
≥2) was recorded in 6 patients. At univariate analysis, we 
found a correlation between acute genitourinary toxicity and 
smoking status (P < 0.001). Statistically significant 
associations (P < 0.05) between late genitourinary toxicity 
and Vx dose levels were calculated from 77 Gy and 77.5 Gy, 
for the “whole bladder” and the “inferior bladder”, 
respectively. For acute toxicity, we found a statistically 
significant correlation with the dose of 80 Gy (P < 0.05), for 
both “whole bladder” and “inferior bladder”. From the NTCP 
cut-off volume model we detected a bladder volume of 6 cc 
as the cut-off volume corresponding to a late genitourinary 
toxicity of 50% at doses ≥77 Gy. 
 
Conclusion: Genitourinary toxicity seems to be correlated 
with bladder maximal doses, quantified as hotspots. 
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Purpose or Objective: Cancer stem cells (CSCs) and hypoxia 
are known contributors of tumour resistance in radiotherapy. 
These parameters influence the radiotherapy schedule for 
optimal tumour control. Since hypofractionation is becoming 
increasingly popular among solid tumours, our aim is to 
evaluate the efficacy of hypo- versus hyperfractionated 
radiotherapy (RT) on hypoxic head and neck cancer (HNC). 
 
Material and Methods: An in silico HNC was developed 
starting from a CSC. To grow a tumour with biologically valid 
parameters, the CSC generates all heterogeneous lineages of 
a tumour, with a probability of CSC symmetrical division 
1.9%, mean cell cycle time 33h and volume doubling time 52 
days. Pre-treatment CSC percentage is 5.9%. Four different 
fractionation schedules have been simulated as shown in 
Table 1. Hypoxic tumours with partial oxygen tension values 
ranging from 3 to 9 mmHg have been treated and tumour 
control assessed.  
 





Results: Treatment resistance is determined by the interplay 
between CSCs and hypoxia. While the modelled conventional 
and hypofractionated RT schedules are biologically 
equivalent, hypofractionation is more efficient on CSC kill 
than conventional treatment. However, for moderately 
hypoxic tumours (6 mmHg partial oxygen tension) (see figure 
1) only hyperfractionated RT offers full control on CSC 
population within the clinically required treatment time. This 
observation might be explained by the advantage of two 
fractions a day through (i) overcoming tumour repopulation 
between consecutive doses, (ii) redistribution of surviving 
cells along the cycle; (iii) better reoxygenation. For each 
decrease in mmHg the number of fractions needed for 
tumour control increases exponentially. This behaviour is also 
influenced by the percentage of CSC, which changes during 
radiotherapy. Thus a tumour with a mean oxygen tension 
below 6 mmHg and a pre-treatment CSC population of 5.9% 
needs a greater than 84Gy dose (overall dose given via 
hyperfractionated RT) or the addition of adjuvant therapies 
in order to be eradicated. 
Figure 1. Radiotherapy schedules for hypoxic HNC with 6 




Conclusion: Hypoxic HNC are better controlled by 
hyperfractionated than by hypofractionated RT. However, 
oxic and mildly hypoxic tumours could benefit from 
hypofractionation, which reduces overall treatment time and 
normal tissue effects. The interplay between CSCs and 
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Purpose or Objective: To correlate a Neural Network (NN) 
predictive model to clinical outcome of toxicities of patients 
undergone Radiation Therapy (RT). A re-plan strategy was 
evaluated highlighting challenges and advantage of an 
Adaptive RT (ART) workload. Clinical outcomes were assessed 
to validate an algorithm based on IGRT and deformable image 
registration. 
 
Material and Methods: A cohort of 30 Head and Neck (H&N) 
patients, previously treated by Tomotherapy and CHT 
concomitant, was investigated: 19 male and 11 female 
[48÷89 years] with mean KPS index 95.5. To take into account 
inter-fractions organ warping, 900 pre-treatment MVCT study 
were deformed by RayStation and a dose accumulation 
analysis was performed. Exported data were used to train the 
predictive NN tool: a MATLAB toolbox developed to identify 
patients eligible for re-planning. Using a retrospective 
approach, the toxicity data were investigated with a mean 
follow-up period of 12 months. Weight (before and after RT), 
smoker number and toxicity information were considered. 
Correlation was assessed using SPSS statistic. 
 
Results: Analysis on the follow-up DB showed that 74% of 
patients were affected by early toxicity: 40% (G1), 25% (G2) 
and 9% (G3); 41% by late toxicity: 30% (G1), 10% (G2) and 1% 
(G3). Correlating the medium-high grade of early toxicity 
with the dose of the event occurred, a 2nd order polynomial 
correlation was detected with a R2 value of 0.93 for G2 and 
0.92 for G3. 
 
 
The correlation of smoking and low toxicity (i.e. dysphagia, 
dysgeusia, mucositis, salivation) showed a mean G1 
increased. An increased frequency of early (21%) and late 
(19%) toxicity was detected for smoker patients, with an 
ANOVA multivariate significance of 3.8% and 0.6% 
respectively. Simultaneously, a NN weekly method was 
carried out to follow and predict anatomical variations during 
RT. A benefit due to a review of the initial plan was 
estimated for 89.6% of patients. The need of re-planning was 
correlated with weight loss. 37% of patients do not need a re-
plan and 25% of them had a weight loss <5%. 63% of patients 
would benefit for a re-plan: during the 2nd week for 25% of 
cases with a weight decrease <10%; during the 4th week for 




Conclusion: The machine learning approaches could support 
decision making in ART workload. Descriptive and inferential 
analysis showed a correlation between NN outcome and 
follow-up data, making robust the predictive approach based 
on organ warping and dose deformation. An increased 
number of cases have to be analyzed to train self-learning 
algorithm and to ensure personalization of patients’ 
treatment. Patients with an abnormal weight loss, smoker 
and with a high dose delivered should be investigated to 
avoid early and late toxicities. 
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Purpose or Objective: In 2012 we started with the 
prospective, electronic registration by the treating physician 
of all grade ≥2 toxicities (CTCAE v4.0) for all patients 
irradiated at our department. Simultaneously we set up an 
infrastructure to couple this data to dose and treatment 
parameters. The aim of this work is to show the feasibility of 
such an infrastructure to audit toxicity prediction models and 
dose constraints in daily clinical practice. 
 
Material and Methods: As a showcase we consider the 
relation between the esophagus V50Gy and grade ≥2 
esophagitis in locally advanced NSCLC patients receiving 
concurrent chemoradiotherapy (CCRT; 24 x 2.75 Gy and daily 
6mg/m2 cisplatin). Clinically we use the criterion V50Gy < 
50% as a dose constraint based on a previously developed 
NTCP model (Kwint et al. IJROBP 2012). The applicability of 
this model to current daily clinical practice, however, is not 
evident since CCRT patients currently receive intravenous 
pre-hydration (1L, NaCl 0.9%) which was shown to decrease 
esophagitis (Uyterlinde et al. R&O 2014).  
For all CCRT patients (excluding re-irradiations of the 
thoracic region) treated since January 2013, the planned 
V50Gy and the registered esophagitis ≥grade 2 were 
automatically retrieved. Patients with toxicity registration in 
at least 50% of the consultations were included. We 
calculated the cumulative incidence of grade ≥2 esophagitis 
per V50Gy and compared this with the expected incidence 
based upon the model by Kwint et al. using a χ2 test. ROC 
analysis was performed to assess the predictive value of 
V50Gy. 
 
Results: For 286 patients, a total of 1842 consultations were 
performed. The incidence of toxicity was electronically 
registered in 76% of these visits. For 229 patients (80%) the 
incidence of toxicity was registered in >50% of consultations. 
Median follow up was 3.5 months. A graphic comparison of 
the observed and predicted incidence of grade ≥2 esophagitis 
is shown in figure 1a. The observed incidence of grade ≥2 
esophagitis was 51.1% while the model predicts 52.1% 
(p=0.89). ROC analysis (figure 1b) resulted in an area under 
the curve of 0.69. To rule out a selection bias towards 
increased toxicity, the analysis was repeated for all 286 
patients, assuming that no toxicity occurred for missing 
registrations, with very similar results. 
